EP0762879A4 - Derives de wortmannine stereochimiques - Google Patents

Derives de wortmannine stereochimiques

Info

Publication number: EP0762879A4
Authority: EP; European Patent Office
Prior art keywords: stereochemical; wortmannin; derivatives; wortmannin derivatives; relates
Prior art date: 1994-07-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP95925483A

Other languages

German (de)

English (en)

Other versions

EP0762879A1 (fr

EP0762879B1 (fr

Inventor

Lawrence Camillo Creemer

Herbert Andrew Kirst

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eli Lilly and Co

Original Assignee

Eli Lilly and Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-07-01

Filing date

1995-06-30

Publication date

1997-10-01

1995-06-30 Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co

1997-03-19 Publication of EP0762879A1 publication Critical patent/EP0762879A1/fr

1997-10-01 Publication of EP0762879A4 publication Critical patent/EP0762879A4/fr

2000-05-10 Application granted granted Critical

2000-05-10 Publication of EP0762879B1 publication Critical patent/EP0762879B1/fr

2015-06-30 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical class C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 title abstract 3
239000002246 antineoplastic agent Substances 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/06—Peri-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Steroid Compounds (AREA)
Compounds Of Unknown Constitution (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

EP95925483A 1994-07-01 1995-06-30 Derives de wortmannine stereochimiques Expired - Lifetime EP0762879B1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/269,716 US5480906A (en)	1994-07-01	1994-07-01	Stereochemical Wortmannin derivatives
US269716		1994-07-01
PCT/US1995/008410 WO1996001108A1 (fr)	1994-07-01	1995-06-30	Derives de wortmannine stereochimiques

Publications (3)

Publication Number	Publication Date
EP0762879A1 EP0762879A1 (fr)	1997-03-19
EP0762879A4 true EP0762879A4 (fr)	1997-10-01
EP0762879B1 EP0762879B1 (fr)	2000-05-10

Family

ID=23028391

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP95925483A Expired - Lifetime EP0762879B1 (fr)	1994-07-01	1995-06-30	Derives de wortmannine stereochimiques

Country Status (10)

Country	Link
US (1)	US5480906A (fr)
EP (1)	EP0762879B1 (fr)
JP (1)	JPH10502373A (fr)
AT (1)	ATE192649T1 (fr)
AU (1)	AU2959995A (fr)
CA (1)	CA2193963A1 (fr)
DE (1)	DE69516866T2 (fr)
ES (1)	ES2145915T3 (fr)
WO (1)	WO1996001108A1 (fr)
ZA (1)	ZA955466B (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2302021A (en) *	1996-10-16	1997-01-08	Lilly Co Eli	Inhibiting bone loss or resorption
US5858753A (en) *	1996-11-25	1999-01-12	Icos Corporation	Lipid kinase
US6413773B1 (en)	1998-06-01	2002-07-02	The Regents Of The University Of California	Phosphatidylinositol 3-kinase inhibitors as stimulators of endocrine differentiation
IL142094A0 (en) *	1998-09-29	2002-03-10	Gamida Cell Ltd	Methods of controlling proliferation and differentiation of stem and progenitor cells
EP2298311B1 (fr) *	1999-01-13	2012-05-09	Bayer HealthCare LLC	Urées de diphényle à substitution omega-carboxyaryle en tant qu'inhibiteurs de la p38 kinase
US8124630B2 (en) *	1999-01-13	2012-02-28	Bayer Healthcare Llc	ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2001024826A2 (fr) *	1999-10-06	2001-04-12	The Brigham And Women's Hospital, Inc.	Composes et procedes de modulation des effets non transcriptionnels des hormones steroides
US6667300B2 (en)	2000-04-25	2003-12-23	Icos Corporation	Inhibitors of human phosphatidylinositol 3-kinase delta
DE60144277D1 (de) *	2000-04-25	2011-05-05	Icos Corp	Hemmer der menschlichen phosphatidyl-inositol-3-kinase delta
AU2002258798A1 (en) *	2001-04-13	2002-10-28	Children's Hospital Medical Center	Methods for the treatment of hepatic disorders
US7371763B2 (en) *	2001-04-20	2008-05-13	Bayer Pharmaceuticals Corporation	Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
GB0119863D0 (en)	2001-08-14	2001-10-10	Cancer Res Campaign Tech	DNA-PK inhibitors
GB0119865D0 (en)	2001-08-14	2001-10-10	Cancer Res Campaign Tech	DNA-PK inhibitors
US6703414B2 (en) *	2001-09-14	2004-03-09	Arizona Board Of Regents On Behalf Of The University Of Arizona	Device and method for treating restenosis
US7081475B2 (en) *	2001-09-14	2006-07-25	Prolx Pharmaceuticals Corp.	Wortmannin analogs and methods of using same
US20080108672A1 (en) *	2002-01-11	2008-05-08	Bernd Riedl	Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
IL152904A0 (en) *	2002-01-24	2003-06-24	Gamida Cell Ltd	Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
EP1465982A4 (fr) *	2002-01-25	2006-06-07	Gamida Cell Ltd	Methodes de developpement de cellules souches et de cellules precurseurs, populations de cellules multipliees obtenues a l'aide de ces methodes
DK1478358T3 (da) *	2002-02-11	2013-10-07	Bayer Healthcare Llc	Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
US7049313B2 (en)	2002-02-25	2006-05-23	Kudos Pharmaceuticals Ltd.	ATM inhibitors
US20050054097A1 (en) *	2002-11-17	2005-03-10	Tony Peled	EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures
US7230139B2 (en) *	2002-12-05	2007-06-12	Gemin X Biotechnologies	Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents
UY28213A1 (es)	2003-02-28	2004-09-30	Bayer Pharmaceuticals Corp	Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
EP1601759A4 (fr) *	2003-03-07	2007-02-14	Gamida Cell Ltd	Extension de populations de cellules souches renouvelables au moyen de modulateurs de kinase pi 3
BRPI0409681A (pt) *	2003-04-23	2006-04-18	Wyeth Corp	derivados de wortmanina solúveis em água
EP1636585B2 (fr) *	2003-05-20	2012-06-13	Bayer HealthCare LLC	Diaryl-urees presentant une activite d'inhibition des kinases
PL1663978T3 (pl) *	2003-07-23	2008-04-30	Bayer Healthcare Llc	Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
KR20060066722A (ko)	2003-08-13	2006-06-16	쿠도스 파마슈티칼스 리미티드	아미노피론 및 ａｔｍ억제제로서의 이의 용도
US20050043239A1 (en) *	2003-08-14	2005-02-24	Jason Douangpanya	Methods of inhibiting immune responses stimulated by an endogenous factor
US20050054614A1 (en) *	2003-08-14	2005-03-10	Diacovo Thomas G.	Methods of inhibiting leukocyte accumulation
LT2612862T (lt)	2004-05-13	2017-01-25	Icos Corporation	Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
WO2005117889A1 (fr) *	2004-05-25	2005-12-15	Icos Corporation	Methodes de traitement et/ou de prevention de la proliferation aberrante des cellules hematopoietiques
US7446124B2 (en) *	2004-07-09	2008-11-04	Prolx Pharmaceuticals Corp.	Wortmannin analogs and methods of using same in combination with chemotherapeutic agents
WO2006030442A2 (fr) *	2004-09-16	2006-03-23	Gamida-Cell Ltd.	Methodes de culture ex vivo de cellules souches et de precurseur par co-culture avec des cellules mesenchymales
RU2408596C2 (ru)	2004-09-20	2011-01-10	Кудос Фармасьютикалс Лимитед	Ингибиторы днк-пк
TW200626610A (en) *	2004-10-13	2006-08-01	Wyeth Corp	Analogs of 17-hydroxywortmannin as PI3K inhibitors
JP2008529995A (ja)	2005-02-09	2008-08-07	クドスファーマシューティカルズリミテッド	Ａｔｍ阻害剤
US20080287469A1 (en) *	2005-02-17	2008-11-20	Diacovo Thomas G	Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation
AR054438A1 (es)	2005-04-15	2007-06-27	Kudos Pharm Ltd	Inhibidores de adn -pk
MX2007013257A (es) *	2005-05-05	2008-01-21	Chroma Therapeutics Ltd	Conjugados de ester de alfa-aminoacido-farmaco hidrolizables por carboxilesterasa.
EP1886138A4 (fr) *	2005-05-11	2009-04-15	Genetic Technologies Ltd	Procédés d'enrichissement de cellules fétales
US8846393B2 (en)	2005-11-29	2014-09-30	Gamida-Cell Ltd.	Methods of improving stem cell homing and engraftment
WO2007120364A2 (fr) *	2005-12-30	2007-10-25	Arizona Board Of Regents, Acting On Behalf Of The University Of Arizona	Metabolites des analogues de la wortmannine et leurs procedes d'utilisation
US9492449B2 (en)	2008-11-13	2016-11-15	Gilead Calistoga Llc	Therapies for hematologic malignancies
KR20170060179A (ko)	2008-11-13	2017-05-31	길리아드 칼리스토가 엘엘씨	혈액 종양에 대한 요법
US20100233733A1 (en) *	2009-02-10	2010-09-16	Nodality, Inc., A Delaware Corporation	Multiple mechanisms for modulation of the pi3 kinase pathway
AU2010229968A1 (en)	2009-03-24	2011-10-13	Gilead Calistoga Llc	Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
JP2012524126A (ja) *	2009-04-20	2012-10-11	ギリアドカリストガリミテッドライアビリティカンパニー	固形腫瘍の治療方法
CA2768843A1 (fr)	2009-07-21	2011-01-27	Gilead Calistoga Llc	Traitement de troubles du foie par des inhibiteurs de pi3k
ES2681703T3 (es) *	2011-03-21	2018-09-14	Vivolux Ab	Tratamiento de tumores sólidos
WO2013121426A1 (fr)	2012-02-13	2013-08-22	Gamida-Cell Ltd.	Culture de cellules souches mésenchymateuses
ES2848273T3 (es)	2012-03-05	2021-08-06	Gilead Calistoga Llc	Formas polimórficas de (S)-2-(1-(9H-purin-6-ilamino)propilo)-5-fluoro-3-fenilquinazolina-4(3H)-ona
US9175266B2 (en)	2012-07-23	2015-11-03	Gamida Cell Ltd.	Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en)	2012-07-23	2017-02-14	Gamida Cell Ltd.	Methods of culturing and expanding mesenchymal stem cells
EP2900667B1 (fr)	2012-09-21	2019-06-05	Vivolux AB	Moyens et procédé pour traiter des tumeurs solides
WO2014203129A1 (fr)	2013-06-19	2014-12-24	Olema Pharmaceuticals, Inc.	Combinaisons de composés benzopyrane, leurs compositions et utilisations
JP2017500319A (ja)	2013-12-20	2017-01-05	ギリアードカリストガエルエルシー	（ｓ）−２−（１−（９ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３ｈ）−オンの塩酸塩の多形形態
EP3083630B1 (fr)	2013-12-20	2019-08-21	Gilead Calistoga LLC	Procédés de synthèse d'inhibiteurs de la phosphatidylinositol 3-kinase
US11021467B2 (en)	2014-06-13	2021-06-01	Gilead Sciences, Inc.	Phosphatidylinositol 3-kinase inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0658343A1 (fr) *	1993-08-25	1995-06-21	Eli Lilly And Company	Utilisation d'hydroxywortmannine-17-bêta et de ses analogues pour la fabrication d'un médicament pour le traitement de maladies dépendant de la phosphatidylinositole-3-kinase

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3668222A (en) *	1969-05-14	1972-06-06	Sandoz Ltd	11-desacetoxy-wortmannin
US4988682A (en) *	1989-02-03	1991-01-29	University Of Pittsburgh	Myo-inositol analogs and method for their use

1994
- 1994-07-01 US US08/269,716 patent/US5480906A/en not_active Expired - Fee Related
1995
- 1995-06-30 EP EP95925483A patent/EP0762879B1/fr not_active Expired - Lifetime
- 1995-06-30 ZA ZA955466A patent/ZA955466B/xx unknown
- 1995-06-30 JP JP8503967A patent/JPH10502373A/ja not_active Ceased
- 1995-06-30 ES ES95925483T patent/ES2145915T3/es not_active Expired - Lifetime
- 1995-06-30 CA CA002193963A patent/CA2193963A1/fr not_active Abandoned
- 1995-06-30 AU AU29599/95A patent/AU2959995A/en not_active Abandoned
- 1995-06-30 DE DE69516866T patent/DE69516866T2/de not_active Expired - Fee Related
- 1995-06-30 WO PCT/US1995/008410 patent/WO1996001108A1/fr not_active Ceased
- 1995-06-30 AT AT95925483T patent/ATE192649T1/de not_active IP Right Cessation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0658343A1 (fr) *	1993-08-25	1995-06-21	Eli Lilly And Company	Utilisation d'hydroxywortmannine-17-bêta et de ses analogues pour la fabrication d'un médicament pour le traitement de maladies dépendant de la phosphatidylinositole-3-kinase

Also Published As

Publication number	Publication date
JPH10502373A (ja)	1998-03-03
WO1996001108A1 (fr)	1996-01-18
DE69516866T2 (de)	2000-10-05
US5480906A (en)	1996-01-02
ATE192649T1 (de)	2000-05-15
ES2145915T3 (es)	2000-07-16
DE69516866D1 (de)	2000-06-15
CA2193963A1 (fr)	1996-01-18
ZA955466B (en)	1996-12-30
AU2959995A (en)	1996-01-25
EP0762879A1 (fr)	1997-03-19
EP0762879B1 (fr)	2000-05-10

Legal Events

Date	Code	Title	Description
1997-01-31	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
1997-03-19	17P	Request for examination filed	Effective date: 19961227
1997-03-19	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE
1997-03-19	AX	Request for extension of the european patent	Free format text: LT PAYMENT 961227;LV PAYMENT 961227;SI PAYMENT 961227
1997-10-01	A4	Supplementary search report drawn up and despatched	Effective date: 19970819
1997-10-01	AK	Designated contracting states	Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE
1998-10-28	17Q	First examination report despatched	Effective date: 19980910
1999-07-10	GRAG	Despatch of communication of intention to grant	Free format text: ORIGINAL CODE: EPIDOS AGRA
1999-10-06	GRAG	Despatch of communication of intention to grant	Free format text: ORIGINAL CODE: EPIDOS AGRA
1999-10-06	GRAH	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOS IGRA
1999-12-16	GRAH	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOS IGRA
2000-03-24	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2000-05-10	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE
2000-05-10	AX	Request for extension of the european patent	Free format text: LT PAYMENT 19961227;LV PAYMENT 19961227;SI PAYMENT 19961227
2000-05-10	LTIE	Lt: invalidation of european patent or patent extension
2000-05-10	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20000510 Ref country code: LI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20000510 Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20000510 Ref country code: CH Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20000510 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20000510 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20000510
2000-05-10	REF	Corresponds to:	Ref document number: 192649 Country of ref document: AT Date of ref document: 20000515 Kind code of ref document: T
2000-05-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2000-05-31	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2000-06-15	REF	Corresponds to:	Ref document number: 69516866 Country of ref document: DE Date of ref document: 20000615
2000-06-30	ET	Fr: translation filed
2000-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20000630 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20000630
2000-07-16	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2145915 Country of ref document: ES Kind code of ref document: T3
2000-08-04	ITF	It: translation for a ep patent filed
2000-08-10	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20000810 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20000810 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20000810
2000-10-02	NLV1	Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
2000-11-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2001-03-17	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2001-03-17	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2001-04-04	REG	Reference to a national code	Ref country code: IE Ref legal event code: MM4A
2001-05-02	26N	No opposition filed
2002-01-01	REG	Reference to a national code	Ref country code: GB Ref legal event code: IF02
2002-05-01	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20020501 Year of fee payment: 8
2002-06-05	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20020605 Year of fee payment: 8
2002-06-14	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: ES Payment date: 20020614 Year of fee payment: 8
2002-06-28	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DE Payment date: 20020628 Year of fee payment: 8
2003-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030630
2003-07-01	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030701
2004-01-01	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040101
2004-02-18	GBPC	Gb: european patent ceased through non-payment of renewal fee	Effective date: 20030630
2004-02-27	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040227
2004-04-02	REG	Reference to a national code	Ref country code: FR Ref legal event code: ST
2004-09-16	REG	Reference to a national code	Ref country code: ES Ref legal event code: FD2A Effective date: 20030701
2005-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20050630

Publication	Publication Date	Title
ZA955466B (en)	1996-12-30	Stereochemical wortmannin derivatives
BG101833A (bg)	1998-04-30	Гуаниново производно
GB9514451D0 (en)	1995-09-13	Sustained-release formulation
MX9703564A (es)	1997-08-30	Inhibidores de proteasa multicatalitica.
ZA981080B (en)	1998-08-12	Bicyclic inhibitors of protein farnesyl transferase
ES2114487A1 (es)	1998-05-16	Mezcla estabilizante sinergistica.
BG102474A (en)	1999-06-30	(-)-cis-6(s)-phenyl-5(r)-[4-(2-pyrrolidine-1-yletoxi)phenyl)-5,6,7 ,8-tetrahydronaphthalen-2-ol-d-tartarate
HU9601857D0 (en)	1996-08-28	New benzyl-piperidine- or -tetrahydro-pyridine derivatives and processes for producing them
GR3019289T3 (en)	1996-06-30	Steroid sulphatase inhibitors
IL114294A0 (en)	1995-10-31	Sterol derivatives
HU9500559D0 (en)	1995-04-28	New mercapto-acetamide tricyclic derivatives as enkephalinase-inhibitors
MX9801190A (es)	1998-04-30	Inhibidores de prolil endopeptidasa.
PL310486A1 (en)	1997-03-17	Novel compounds, derivatives of genistein
GB9611614D0 (en)	1996-08-07	Process for inhibiting the effect of flourescent whitening agents
BG103649A (en)	2000-06-30	Method for the preparation of eprosartan
AU1160700A (en)	2000-05-29	Ppar gamma ligands
ZA976854B (en)	1998-03-19	Treatment of psychotic disorders.
BG103650A (en)	2000-06-30	Method for the preparation of eprosartan
IL128186A0 (en)	1999-11-30	Intermediates for the preparation of 2-imidazoline-5-ones
ZA949564B (en)	1995-08-16	Method for treating constipation using dimeticone.
EP0651643A4 (fr)	1995-10-04	STEROIDES 17-AKYLCETONIQUES UTILES COMME INHIBITEURS DE 5--g(a)-REDUCTASE.
MX9606009A (es)	1997-08-30	Uso de 8,9-deshidroestrona como un antioxidante.
BG103321A (en)	2001-08-31	Method for the preparation of phenoxyphenylsulphonyl halogenides
YU71400A (sh)	2003-04-30	Poboljšani postupak za pripremanje farmaceutski dragocenih derivata norbenzomorfana
MX9603450A (es)	1997-03-29	Procedimiento para la obtencion de aminotriazolinas substituidas.